{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T02:53:00Z","timestamp":1782874380503,"version":"3.54.5"},"reference-count":23,"publisher":"Japanese Society of Internal Medicine","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,5,15]]},"DOI":"10.2169\/internalmedicine.5027-24","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T22:12:36Z","timestamp":1741385556000},"page":"1591-1594","source":"Crossref","is-referenced-by-count":1,"title":["Double-seropositive Myasthenia Gravis Following COVID-19"],"prefix":"10.2169","volume":"64","author":[{"given":"Yuki","family":"Hiraoka","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Hamamatsu Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Hosoi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hamamatsu Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Tsubata","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hamamatsu Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miharu","family":"Yanagida","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hamamatsu Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Otake","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hamamatsu Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hamamatsu Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Li M, Ren L, Zhang Y, et al. Clinical characteristics of AChRAb and MuSKAb double seropositive myasthenia gravis patients. Clin Neurol Neurosurg 172: 69-73, 2018.","DOI":"10.1016\/j.clineuro.2018.06.041"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Sieb JP. Myasthenia gravis: an update for the clinician. Clin Exp Immunol 175: 408-418, 2014.","DOI":"10.1111\/cei.12217"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Taga A, Lauria G. COVID-19 and the peripheral nervous system. A 2-year review from the pandemic to the vaccine era. J Peripher Nerv Syst 27: 4-30, 2022.","DOI":"10.1111\/jns.12482"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Paliwal VK, Garg RK, Gupta A, Tejan N. Neuromuscular presentations in patients with COVID-19. Neurol Sci 41: 3039-3056, 2020.","DOI":"10.1007\/s10072-020-04708-8"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Finsterer J, Scorza FA, Scorza C, Fiorini A. COVID-19 associated cranial nerve neuropathy: a systematic review. Bosn J Basic Med Sci 22: 39-45, 2022.","DOI":"10.17305\/bjbms.2021.6341"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Shah SMI, Yasmin F, Memon RS, et al. COVID-19 and myasthenia gravis: a review of neurological implications of the SARS-COV-2. Brain Behav 12: e2789, 2022.","DOI":"10.1002\/brb3.2789"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Gilhus NE. Myasthenia gravis. N Engl J Med 375: 2570-2581, 2016.","DOI":"10.1056\/NEJMra1602678"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Croitoru CG, Cuciureanu DI, Hodorog DN, Grosu C, Cianga P. Autoimmune myasthenia gravis and COVID-19. A case report-based review. J Int Med Res 51: 3000605231191025, 2023.","DOI":"10.1177\/03000605231191025"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Poulas K, Koutsouraki E, Kordas G, Kokla A, Tzartos SJ. Anti-MuSK- and anti-AChR-positive myasthenia gravis induced by d-penicillamine. J Neuroimmunol 250: 94-98, 2012.","DOI":"10.1016\/j.jneuroim.2012.05.011"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Zouvelou V, Zisimopoulou P, Psimenou E, Matsigkou E, Stamboulis E, Tzartos SJ. AChR-myasthenia gravis switching to double-seropositive several years after the onset. J Neuroimmunol 267: 111-112, 2014.","DOI":"10.1016\/j.jneuroim.2013.12.012"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Li M, Ren L, Zhang Y, et al. Clinical characteristics of AChRAb and MuSKAb double seropositive myasthenia gravis patients. Clin Neurol Neurosurg 172: 69-73, 2018.","DOI":"10.1016\/j.clineuro.2018.06.041"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Zhang J, Chen Y, Chen J, et al. AChRAb and MuSKAb double-seropositive myasthenia gravis: a distinct subtype? Neurol Sci 42: 863-869, 2021.","DOI":"10.1007\/s10072-021-05042-3"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. He T, Chen K, Li Y, Luo Z, Luo M, Yang H. Clinical features and prognostic analysis of MuSK-antibody-positive myasthenia gravis versus double-seropositive myasthenia gravis: a single-center study from central south China. Neuropsychiatr Dis Treat 20: 725-735, 2024.","DOI":"10.2147\/NDT.S450651"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Bhibhatbhan A, Kline G, Vincent A, Toth C. Anti-MuSK myasthenia gravis presenting with Epstein-Barr virus-associated mononucleosis and immune-mediated diabetes mellitus. Muscle Nerve 36: 264-266, 2007.","DOI":"10.1002\/mus.20746"},{"key":"15","unstructured":"15. Saha A, Batra P, Vilhekar KY, Chaturvedi P. Post-varicella myasthenia gravis. Singapore Med J 48: e177-e180, 2007."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Restivo DA, Centonze D, Alesina A, Marchese-Ragona R. Myasthenia gravis associated with SARS-CoV-2 infection. Ann Intern Med 173: 1027-1028, 2020.","DOI":"10.7326\/L20-0845"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Muhammed L, Baheerathan A, Cao M, Leite MI, Viegas S. MuSK antibody-associated myasthenia gravis with SARS-CoV-2 infection: a case report. Ann Intern Med 174: 872-873, 2021.","DOI":"10.7326\/L20-1298"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kopa\u0144ska M, Batoryna M, Bartman P, Szczygielski J, Bana\u015b-Z\u0105bczyk A. Disorders of the cholinergic system in COVID-19 era - a review of the latest research. Int J Mol Sci 23: 672, 2022.","DOI":"10.3390\/ijms23020672"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Venkatakrishnan AJ, Kayal N, Anand P, Badley AD, Church GM, Soundararajan V. Benchmarking evolutionary tinkering underlying human-viral molecular mimicry shows multiple host pulmonary-arterial peptides mimicked by SARS-CoV-2. Cell Death Discov 6: 96, 2020.","DOI":"10.1038\/s41420-020-00321-y"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kanduc D. Exposure to SARS-CoV-2 and infantile diseases. Glob Med Genet 10: 72-78, 2023.","DOI":"10.1055\/s-0043-1768699"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Farsalinos K, Eliopoulos E, Leonidas DD, Papadopoulos GE, Tzartos S, Poulas K. Nicotinic cholinergic system and COVID-19: in silico identification of an interaction between SARS-CoV-2 and nicotinic receptors with potential therapeutic targeting implications. Int J Mol Sci 21: 5807, 2020.","DOI":"10.3390\/ijms21165807"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Darmarajan T, Paudel KR, Candasamy M, et al. Autoantibodies and autoimmune disorders in SARS-CoV-2 infection: pathogenicity and immune regulation. Environ Sci Pollut Res Int 29: 54072-54087, 2022.","DOI":"10.1007\/s11356-022-20984-7"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Ca\u00f1as CA. The triggering of post-COVID-19 autoimmunity phenomena could be associated with both transient immunosuppression and an inappropriate form of immune reconstitution in susceptible individuals. Med Hypotheses 145: 110345, 2020.","DOI":"10.1016\/j.mehy.2020.110345"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/10\/64_5027-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T03:27:22Z","timestamp":1747452442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/10\/64_5027-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5027-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]},"article-number":"5027-24"}}